A new HIV prevention treatment could revolutionize care for those at high risk of infection. The FDA is reviewing lenacapavir, a twice-yearly injectable PrEP, which, if approved, would be the first of its kind. Unlike daily oral medications, this long-acting injection could improve adherence and offer a more discreet option.
Gilead Sciences’ lenacapavir has already shown success in clinical trials, blocking HIV from entering cells and reducing infection risk. Experts believe this could help close healthcare gaps, especially for vulnerable communities with limited access to traditional treatments. Dr. Dietmar Berger of Gilead called it a “game-changer” in the fight against HIV.
While this medical advancement offers hope, concerns remain over proposed cuts to HIV funding in the U.S. Advocacy groups are rallying to protect critical resources that support prevention and treatment. With ongoing congressional debates, maintaining financial support is crucial to ensuring continued progress in ending the HIV epidemic.